ArticleThe lancet. HIV2020

Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.

Andrew N Phillips et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.